Tempus AI
Links clinical testing, multimodal data, and AI applications across precision medicine.
Something off on this page? Send us feedback.
Profile
Sells oncology and hereditary diagnostics alongside data licensing, clinical-trial services, care-pathway software, and algorithmic applications. A shared multimodal data platform connects the testing and data businesses within one reportable segment, with operations based in Chicago and an extension into Japan through a joint venture.
Combines clinical diagnostics with a multimodal data platform for physicians and life-sciences customers. Diagnostics spans oncology and hereditary testing, while Data and applications includes Insights, Next, Trials, and Algos.
Laboratory testing generates molecular and clinical data that can be structured and de-identified for licensing, research, trial matching, care-gap identification, and algorithmic tools. This feedback loop connects the testing business with the software and data products.
Based in Chicago, the business operates as one reportable segment and extends its model into Japan through the SB Tempus joint venture. Execution depends on payer coverage and reimbursement, pharmaceutical and biotechnology research budgets, compliance with health-data and AI rules, and integration of acquired laboratories, datasets, software, and teams.
Company facts
Key statistics
Year to date +2.6% · Average volume (30d) 6.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Reiterate | Neutral | $105 | $56 | |
| Aug 3, 2026 | BTIG | Reiterate | Buy | $80 | $70 | |
| Aug 3, 2026 | H.C. Wainwright | Target | $64 | $56 | ||
| Aug 3, 2026 | Stifel Nicolaus | Target | $60 | $50 | ||
| Jul 20, 2026 | Lake Street | Downgrade | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.14 | −$0.04 | +72.0% | $379.7M | $382.5M | +0.7% | −0.95% |
| May 5, 2026Q1 FY26 | −$0.21 | −$0.13 | +38.1% | $345.4M | $348.1M | +0.8% | −1.05% |
| Feb 24, 2026Q4 FY25 | −$0.04 | −$0.04 | +8.8% | $362.6M | $367.2M | +1.3% | −7.32% |
| Nov 4, 2025Q3 FY25 | −$0.17 | −$0.11 | +36.2% | $328.7M | $334.2M | +1.7% | −2.64% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $255.7M | $314.6M | $334.2M | $367.2M | $348.1M | $382.5M | |
| Gross profit | $155.2M | $195.0M | $209.9M | $237.7M | $222.0M | $246.5M | |
| Operating income | −$68.7M | −$61.8M | −$61.0M | −$61.4M | −$84.7M | −$75.9M | |
| Net income | −$68.0M | −$42.8M | −$80.0M | −$54.2M | −$125.9M | $5.6M | |
| Diluted EPS | −$0.40 | −$0.25 | −$0.46 | −$0.30 | −$0.71 | $0.03 | |
| Gross margin | 60.7% | 62.0% | 62.8% | 64.7% | 63.8% | 64.4% | |
| Operating margin | -26.9% | -19.6% | -18.3% | -16.7% | -24.3% | -19.8% |
Fiscal years (4-quarter sums)FY20 $188.0M · FY21 $257.9M · FY23 $531.8M · FY24 $693.4M · FY25 $1.27B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $816.0M · Total debt $1.44B · Total assets $2.37B · Shareholders' equity $444.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 175.20M · Float 106.50M · 60.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Eric Paul Lefkofsky | 42.77M | 24.00% | 13G | Feb 10, 2026 |
| Bradley A. Keywell | 12.85M | 7.60% | 13G | May 15, 2025 |
| Ark Investment Management LLC | 10.02M | 5.72% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 8.29M | 4.73% | 13F | Aug 7, 2026 |
| Baillie Gifford & Co | 8.19M | 4.67% | 13F | Aug 6, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Eric P. Lefkofsky | director, 10 percent owner, officer: CEO and Chairman | −250,000 | $68.46 |
| Aug 21, 2026 | Ryan Fukushima | officer: CEO, Data | −14,286 | $70.00 |
| Aug 21, 2026 | Thomas Edward Schoenherr | officer: CEO, Diagnostics | −2,694 | $70.00 |
| Aug 18, 2026 | Ryan M. Bartolucci | officer: Chief Accounting Officer | −6,175 | $49.61 |
| Aug 19, 2026 | Andrew Polovin | officer: EVP, Chief Legal Officer | −7,927 | $56.00 |
Peers
- Caris Life Sciences
Closest public peer in tumor profiling, liquid biopsy, and oncology data
- Guardant Health
Direct rival in oncology testing, MRD, and clinico-genomic data
- Natera
Major MRD rival with adjacent tumor profiling and hereditary testing
- NeoGenomics
Oncology lab network spanning diagnostics, MRD, trials, and data
- IQVIA
Scaled rival in life-sciences data, real-world evidence, and trials
- GeneDx
Direct hereditary-testing rival built on clinical exome and genome sequencing
- Myriad Genetics
Hereditary cancer and neuropsychiatric pharmacogenomics competitor
- Labcorp
Large lab rival in oncology, hereditary genetics, and MRD testing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| GeneDx | $87.15 | +0.93% | $2.57B | — | 132.3 | 5.7 | +11.4% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Median | 32.5 | 64.9 | 4.1 | +11.3% |